Lilly Diabetes Donates 91 Scholarships to American Diabetes Association's Summer Camp Program
PTSM: Pharmaceutical Technology Sourcing and Management
Lilly Diabetes supports the American Diabetes Association for the seventh year in a row.
Lilly Diabetes
announced its support for the American Diabetes Association's summer camp program for the seventh year in a row with a donation of $91,000 that will send 91 children to diabetes camp this summer. Since 2008, Lilly Diabetes has supported 531 children attending diabetes camps throughout the US, a scholarship donation totaling over half a million dollars.
Today, there are approximately 130 diabetes camps nationwide. The Association is the single largest operator of US camps for children with diabetes, with 40 camps offering 49 sessions in 25 states each summer. In the last decade, Lilly has donated more than $20 million in insulin and other diabetes medicines, educational materials, volunteers, scholarships, and motivational speakers, making it one of the largest supporters of diabetes camps in the country.
Camp scholarships are awarded by the Association based on financial need.
Source:
Lilly Diabetes
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
